DK163931C - Fremgangsmaade til fremstilling af hbsag, en dna-vektor og en gaercelle indeholdende denne dna-vektor til brug ved fremgangsmaaden - Google Patents

Fremgangsmaade til fremstilling af hbsag, en dna-vektor og en gaercelle indeholdende denne dna-vektor til brug ved fremgangsmaaden

Info

Publication number
DK163931C
DK163931C DK347682A DK347682A DK163931C DK 163931 C DK163931 C DK 163931C DK 347682 A DK347682 A DK 347682A DK 347682 A DK347682 A DK 347682A DK 163931 C DK163931 C DK 163931C
Authority
DK
Denmark
Prior art keywords
yeast
hbsag
synthesis
dna vector
purified
Prior art date
Application number
DK347682A
Other languages
Danish (da)
English (en)
Other versions
DK347682A (da
DK163931B (da
Inventor
William J Rutter
Pablo D T Valenzuela
Benjamin D Hall
Gustav Ammerer
Original Assignee
Univ California
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23113710&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK163931(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ California, Univ Washington filed Critical Univ California
Publication of DK347682A publication Critical patent/DK347682A/da
Publication of DK163931B publication Critical patent/DK163931B/da
Application granted granted Critical
Publication of DK163931C publication Critical patent/DK163931C/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK347682A 1981-08-04 1982-08-03 Fremgangsmaade til fremstilling af hbsag, en dna-vektor og en gaercelle indeholdende denne dna-vektor til brug ved fremgangsmaaden DK163931C (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28991581A 1981-08-04 1981-08-04
US28991581 1981-08-04

Publications (3)

Publication Number Publication Date
DK347682A DK347682A (da) 1983-02-05
DK163931B DK163931B (da) 1992-04-21
DK163931C true DK163931C (da) 1992-09-14

Family

ID=23113710

Family Applications (2)

Application Number Title Priority Date Filing Date
DK347682A DK163931C (da) 1981-08-04 1982-08-03 Fremgangsmaade til fremstilling af hbsag, en dna-vektor og en gaercelle indeholdende denne dna-vektor til brug ved fremgangsmaaden
DK114791A DK169152B1 (da) 1981-08-04 1991-06-14 Fremgangsmåde til fremstilling af et antistof mod HBsAg

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK114791A DK169152B1 (da) 1981-08-04 1991-06-14 Fremgangsmåde til fremstilling af et antistof mod HBsAg

Country Status (12)

Country Link
EP (1) EP0072318B1 (sv)
JP (1) JPS5877823A (sv)
AT (1) ATE123225T1 (sv)
CA (1) CA1341642C (sv)
DE (2) DE3280186D1 (sv)
DK (2) DK163931C (sv)
ES (1) ES8400877A1 (sv)
GR (1) GR76274B (sv)
HK (1) HK64591A (sv)
IE (1) IE65996B1 (sv)
PT (1) PT75374B (sv)
SG (1) SG58191G (sv)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ201705A (en) * 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
JPS58146281A (ja) * 1981-10-19 1983-08-31 Suntory Ltd 酵母細胞の形質転換法
EP0105149B1 (en) * 1982-08-16 1990-05-16 Science and Technology Agency, Minister's Secretariat, Director of Finance Division Recombinant plasmid containing hepatitis b virus gene, yeast transformed with said recombinant plasmid, and production of hepatitis b virus surface antigen
AU584580B2 (en) * 1982-09-08 1989-06-01 Smith Kline - Rit Hepatitis B virus vaccine
US4876197A (en) * 1983-02-22 1989-10-24 Chiron Corporation Eukaryotic regulatable transcription
CA1341116C (en) * 1983-02-22 2000-10-17 Rae Lyn Burke Yeast expression systems with vectors having gapdh or pyk promoters and synthesis or foreign protein
JPS6078999A (ja) * 1983-10-05 1985-05-04 Chemo Sero Therapeut Res Inst ＨＢｓ抗原の精製方法
JPS60104020A (ja) * 1983-10-14 1985-06-08 メルク　エンド　カムパニー　インコーポレーテツド Ａ型肝炎‐タンパク質サブユニツト抗原
ATE102250T1 (de) * 1984-05-11 1994-03-15 Chiron Corp Erhoehte hefetranskription unter verwendung einer hybridkonstruktion der promotorregion.
EP0174444B1 (en) * 1984-06-18 1992-03-11 Chiron Corporation Hepatitis surface antigen particle vaccine
US4624918A (en) * 1984-07-09 1986-11-25 Genentech, Inc. Purification process for hepatitis surface antigen and product thereof
US4722840A (en) * 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
ATE70308T1 (de) * 1984-09-12 1991-12-15 Chiron Corp Hybridpartikel-immunogene.
JP2615027B2 (ja) * 1985-04-08 1997-05-28 アムジェン インコーポレイテッド 外来遺伝子の転写を制御するための方法及びハイブリッドプロモーター
US4649192A (en) * 1985-05-30 1987-03-10 Smith Kline-Rit Method for the isolation and purification of hepatitis B surface antigen using polysorbate
CA1288075C (en) * 1985-08-15 1991-08-27 John C. Fieschko Fermentation methods for hepatitis vaccine production
JP2810364B2 (ja) * 1985-10-04 1998-10-15 ジ・アップジョン・カンパニー 偽狂犬病ウイルス蛋白質
US4935349A (en) * 1986-01-17 1990-06-19 Zymogenetics, Inc. Expression of higher eucaryotic genes in aspergillus
US4816564A (en) * 1986-01-31 1989-03-28 Merck & Co., Inc. Method for producing hepatitis B virus proteins in yeast
JPH0768267B2 (ja) * 1986-06-05 1995-07-26 財団法人阪大微生物病研究会 フラビウイルス抗原
JPH0789951B2 (ja) * 1986-06-18 1995-10-04 財団法人阪大微生物病研究会 遺伝子発現産物の精製法
JPH089637B2 (ja) * 1986-06-18 1996-01-31 財団法人阪大微生物病研究会 Ｂ型肝炎ウイルス抗原とその製造法
IL79740A0 (en) * 1986-08-17 1986-11-30 Yeda Res & Dev Hepatitis vaccine
AU606627B2 (en) * 1986-11-01 1991-02-14 British Bio-Technology Limited Particulate hybrid hiv antigens
DE3882154T2 (de) * 1987-02-27 1993-12-02 Merck & Co Inc Verfahren zur Herstellung des pres 1/S2/S-Hepatitis-B-Antigens aus Hefe.
US5026828A (en) * 1987-02-27 1991-06-25 Merck & Co., Inc. Method of purifying recombinant pres-1/S-2/S/S hepatitis B antigen from yeast
CA1341074C (en) 1987-06-22 2000-08-08 Hans A. Thoma Hbv surface antigen particles, prepared by recombinant dna processes, composed of different epitopes, selected from the pre-s and s-peptides as a new vaccine
US5011915A (en) * 1987-10-26 1991-04-30 Merck & Co., Inc. Process for purifying recombinant hepatitis antigens
NZ228948A (en) * 1988-05-13 1991-06-25 Phillips Petroleum Co Hbv particles containing s and pre-s 2 proteins and recombinant processes for their production in yeast cells
EP0491077A1 (en) * 1990-12-19 1992-06-24 Medeva Holdings B.V. A composition used as a therapeutic agent against chronic viral hepatic diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2270892A1 (en) * 1974-05-14 1975-12-12 Inst Francais D Immunologie Vaccines from attenuated viruses - which have been serially incubated with yeast cells, especially Saccharomyces cerevisiae
DD147855A5 (de) * 1978-12-22 1981-04-22 Biogen Nv Verfahren zur erzeugung mindestens eines hbv-antigenwirkung aufweisenden polypeptids
IE52036B1 (en) * 1979-05-24 1987-05-27 Univ California Non-passageable viruses
FR2480780B1 (fr) * 1980-04-22 1985-12-06 Pasteur Institut Procede de transformation de cellules, notamment eucaryotes, par un adn circulaire tel que celui du virus de l'hepatite b et preparations contenant les produits d'expression desdits adn
JPH0314840A (ja) * 1988-12-28 1991-01-23 Kureha Chem Ind Co Ltd 弗化ビニリデン系ポリマー二軸冷延伸フィルムおよびその製造方法

Also Published As

Publication number Publication date
ATE123225T1 (de) 1995-06-15
DE3280468T2 (de) 1995-12-07
EP0072318A2 (en) 1983-02-16
ES514712A0 (es) 1983-11-16
DK347682A (da) 1983-02-05
EP0072318A3 (en) 1983-03-16
SG58191G (en) 1993-02-19
JPH0526798B2 (sv) 1993-04-19
DE3280186D1 (de) 1990-07-05
GR76274B (sv) 1984-08-04
PT75374A (en) 1982-09-01
DE3280468D1 (de) 1995-07-06
ES8400877A1 (es) 1983-11-16
EP0072318B1 (en) 1990-05-30
CA1341642C (en) 2023-02-21
PT75374B (en) 1985-12-13
DK114791D0 (da) 1991-06-14
DK163931B (da) 1992-04-21
JPS5877823A (ja) 1983-05-11
HK64591A (en) 1991-08-23
IE65996B1 (en) 1995-11-29
DK114791A (da) 1991-06-14
DK169152B1 (da) 1994-08-29

Similar Documents

Publication Publication Date Title
DK163931C (da) Fremgangsmaade til fremstilling af hbsag, en dna-vektor og en gaercelle indeholdende denne dna-vektor til brug ved fremgangsmaaden
HU904615D0 (en) New antigens and process for producing them
US5024938A (en) Recombinant DNA inserted with hepatitis B virus gene, mammalian cells transformed with cloned viral DNA, and production of hepatitis B virus proteins
EP0291586A3 (en) Recombinant hepatitis b surface antigen and vaccine containing it
DE3279568D1 (en) Method for expressing a gene
ATE91718T1 (de) Rekombinante dns-molekuele die hepatitis-boberfl|chenantigenkodieren, deren herstellung und abgeleitete vakzine.
EP0105141A3 (en) Recombinant dna molecules, process for their production, their use for production of hepatitis b surface antigen (hbsag) and pharmaceutical compositions containing this hbsag
EP0340806A3 (en) Synthesis of human virus antigens by yeast
DK0485504T3 (da) Fremgangsmåde til fremstilling af aktiveret protein C ved celledyrkning
ATE109353T1 (de) Verfahren zur herstellung eines impfstoffs gegen hepatitis b.
WO1990010058A3 (en) Method for production and purification of hepatitis b vaccine
FI98466C (sv) FSME-virusets västliga subtyps isolerade DNA- och RNA-molekyler vektorer innehållande dessa och cellodlingar och ett förfarande för framställning av peptider kodande för dessa
JPS57209298A (en) Recombinant dna, its preparation, and host transformed therewith
MY106731A (en) Novel antigens and methods therefor

Legal Events

Date Code Title Description
PUP Patent expired